HumaGene has developed IP processes for producing human fibrinogen and thrombin. With $1.2 MM in new funding, HumaGene will become profitable in 18 months.
Only investors on Gust who have been granted access can view this content.
Interested in this startup? Sign In or Sign Up to request more information.
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.
Get Started for Free